Selected article for: "ground glass and pulmonary distribution"

Author: De Cobelli, Francesco; Palumbo, Diego; Ciceri, Fabio; Landoni, Giovanni; Ruggeri, Annalisa; Rovere-Querini, Patrizia; D'Angelo, Armando; Steidler, Stephanie; Galli, Laura; Poli, Andrea; Fominskiy, Evgeny; Calabrò, Maria Grazia; Colombo, Sergio; Monti, Giacomo; Nicoletti, Roberto; Esposito, Antonio; Conte, Caterina; Dagna, Lorenzo; Ambrosio, Alberto; Scarpellini, Paolo; Ripa, Marco; Spessot, Marzia; Carlucci, Michele; Montorfano, Matteo; Agricola, Eustachio; Baccellieri, Domenico; Bosi, Emanuele; Tresoldi, Moreno; Castagna, Antonella; Martino, Gianvito; Zangrillo, Alberto
Title: Pulmonary Vascular Thrombosis in COVID-19 Pneumonia
  • Cord-id: 5lhmwf2o
  • Document date: 2021_1_13
  • ID: 5lhmwf2o
    Snippet: OBJECTIVES: During SARS-CoV-2 infection, dramatic endothelial cell damage with pulmonary microvascular thrombosis has been hypothesized to occur. Our aim was to assess whether pulmonary vascular thrombosis is due to recurrent thromboembolism from peripheral deep vein thrombosis or rather to local inflammatory endothelial damage with a superimposed thrombotic late complication. DESIGN: Observational study SETTING: Medical and intensive care unit wards of a teaching hospital PARTICIPANTS: We repor
    Document: OBJECTIVES: During SARS-CoV-2 infection, dramatic endothelial cell damage with pulmonary microvascular thrombosis has been hypothesized to occur. Our aim was to assess whether pulmonary vascular thrombosis is due to recurrent thromboembolism from peripheral deep vein thrombosis or rather to local inflammatory endothelial damage with a superimposed thrombotic late complication. DESIGN: Observational study SETTING: Medical and intensive care unit wards of a teaching hospital PARTICIPANTS: We report a subset of patients included in a prospective institutional study (CovidBiob study) with clinical suspicion of pulmonary vascular thromboembolism. INTERVENTIONS: Computed Tomography Pulmonary Angiography and evaluation of laboratory markers and coagulation profile. MEASUREMENTS AND MAIN RESULTS: Twenty-eight out of 55 (50.9%) patients enrolled showed pulmonary vascular thrombosis, with a median time interval from symptoms onset of 17.5 days. Simultaneous multiple pulmonary vascular thromboses were identified in 22 cases, with bilateral involvement in 16, mostly affecting segmental/subsegmental pulmonary arteries branches (67.8% and 96.4%). Patients with pulmonary vascular thrombosis had significantly higher ground glass opacities areas (31.7% [22.9-41] vs. 17.8% [10.8-22.1] p<0.001) compared to those without pulmonary vascular thrombosis. D-Dimer level at hospital admission was predictive of pulmonary vascular thrombosis. CONCLUSIONS: Our findings identify a specific radiological pattern of COVID-19 pneumonia with a unique spatial distribution of pulmonary vascular thrombosis overlapping areas of ground glass opacities. These findings support the hypothesis of a pathogenetic relationship between COVID-19 lung inflammation and pulmonary vascular thrombosis and challenge the previous definition of pulmonary embolism associated with COVID-19 pneumonia.

    Search related documents:
    Co phrase search for related documents
    • absence presence and active inflammation: 1
    • absence presence and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • absence presence and lobe artery: 1
    • absence presence and local thrombosis: 1
    • absence presence and low molecular weight: 1, 2, 3
    • absence presence and low molecular weight heparin: 1
    • academic hospital and acute ards respiratory distress syndrome: 1
    • academic hospital and low molecular weight: 1, 2
    • active inflammation and acute ards respiratory distress syndrome: 1, 2
    • active inflammation and low molecular weight: 1, 2
    • active inflammation and low molecular weight heparin: 1
    • acute ards respiratory distress syndrome and additional icu: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and local thrombosis: 1
    • acute ards respiratory distress syndrome and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • local thrombosis and low molecular weight: 1